a new approach to life science presentation 2017.2.pdf · onelife sa: a new approach… onelife is...
TRANSCRIPT
© 2017 Onelife
Ongoing projects • Onelife Fund • Private Equity Vehicle (Onelife AG) • Services to companies, financial
institutions, and family offices • Collaboration with non-profit
organizations • Free advisory to Life Science start-up • Scouting for assets acquisition • New companies start-up
2
Onelife SA: a new approach…
ONELIFE is a Swiss consultancy company with long expertise in healthcare and biotech. ONELIFE uses a network of highly experienced consultants applying ethical considerations and commitment.
Member of:
© 2017 Onelife 3
Our key team Enrico Braglia, M.Sc (Economics), ONELIFE founder has over 25 years in healthcare in top executive positions and boards. He is involved in a number of professional and no profit international organizations, founder and board member in several innovative companies.
Federica Pericle, PhD, MBA, ONELIFE Scientific and Strategic Advisor has over 25 years in research and development in public institutions, universities and in top executive position and boards in US companies.
Massimo Colnago, M.Sc (Economics) ONELIFE Equity Analyst has over 20 years in capital markets, portfolio analysis, wealth management and trading in Switzerland and UK.
Anastasia Perekrest
Esperta in Fiscalità, Contabilità e Gestione societaria.
Fluente in 4 lingue (Eng, Ita, Fra, Rus)
Via Civra 11, CH - 6926 Montagnola 076 48 98 553 Email: [email protected] Permesso B dal 2011 Cittadinanza: Italia, Lussemburgo, Russia Data di nascita: 23.06.1979 Stato civile: coniugata
S I N T E S I Ottime competenze in fiscalità, contabilità e gestione societaria. Esperienza di lavoro locale e internazionale, fluente in quattro lingue (eng, fra, ita, rus), approccio al lavoro concreto e proattivo.
E S P E R I E N Z E P R O F E S S I O N A L I Ges to r e S oc i e t a r io e Ass i s t en te d i D i r ez ione 03/2012 – 06/2015 | Fidium S.A., Fiduciaria a Lugano
- Gestione società svizzere ed estere, controllo e gestione aspetti amministrativi, finanziari e fiscali.
- Family Office: pratiche permessi di residenza, aspetti fiscali e “relocation”.
- Gestione della contrattualistica (dipendenti, collaboratori e fornitori) Cons u l en te F i s ca le e Ass i s t en te U f f i c io 05/2011 – 02/2012 | Studio Legale Avv. Prospero, Lugano
- Costituzione e gestione di aspetti amministrativi, fiscali e contabili di aziende svizzere e offshore.
- Gestione fatturazione dello Studio, aiuto contabilità e comunicazione con Clienti.
Cons u l en te 07/2009 – 05/2011 | Bruce Clay, Agenzia Americana a Milano
- Gestione aspetti amministrativi e contabili. - Aggiornamento sito corporate e campagne su Google per i clienti
internazionali francesi e russi.
As s i s ten t e D i r ez iona l e 10/2007 – 06/2009 | Traverso & Associati, Studio Legale e Tributario, Milano
- Gestione rapporti e corrispondenza con i clienti internazionali in USA, Francia e Gran Bretagna.
- Gestione degli aspetti tributari della parcellazione internazionale. Cons u l en te “G rand i C l i en t i ” 06/2001 – 10/2007 | Hoogewerf & Cie, una società Fiduciaria importante, Lussemburgo
- Consulenza fiscale internazionale relativa alla tassazione d’impresa (dividendi, royalties, interessi) e persone fisiche.
- Costituzione società Lussemburgo e offshore, gestione degli aspetti
Anastasia Perekrest
Esperta in Fiscalità, Contabilità e Gestione societaria.
Fluente in 4 lingue (Eng, Ita, Fra, Rus)
Via Civra 11, CH - 6926 Montagnola 076 48 98 553 Email: [email protected] Permesso B dal 2011 Cittadinanza: Italia, Lussemburgo, Russia Data di nascita: 23.06.1979 Stato civile: coniugata
S I N T E S I Ottime competenze in fiscalità, contabilità e gestione societaria. Esperienza di lavoro locale e internazionale, fluente in quattro lingue (eng, fra, ita, rus), approccio al lavoro concreto e proattivo.
E S P E R I E N Z E P R O F E S S I O N A L I Ges to r e S oc i e t a r io e Ass i s t en te d i D i r ez ione 03/2012 – 06/2015 | Fidium S.A., Fiduciaria a Lugano
- Gestione società svizzere ed estere, controllo e gestione aspetti amministrativi, finanziari e fiscali.
- Family Office: pratiche permessi di residenza, aspetti fiscali e “relocation”.
- Gestione della contrattualistica (dipendenti, collaboratori e fornitori) Cons u l en te F i s ca le e Ass i s t en te U f f i c io 05/2011 – 02/2012 | Studio Legale Avv. Prospero, Lugano
- Costituzione e gestione di aspetti amministrativi, fiscali e contabili di aziende svizzere e offshore.
- Gestione fatturazione dello Studio, aiuto contabilità e comunicazione con Clienti.
Cons u l en te 07/2009 – 05/2011 | Bruce Clay, Agenzia Americana a Milano
- Gestione aspetti amministrativi e contabili. - Aggiornamento sito corporate e campagne su Google per i clienti
internazionali francesi e russi.
As s i s ten t e D i r ez iona l e 10/2007 – 06/2009 | Traverso & Associati, Studio Legale e Tributario, Milano
- Gestione rapporti e corrispondenza con i clienti internazionali in USA, Francia e Gran Bretagna.
- Gestione degli aspetti tributari della parcellazione internazionale. Cons u l en te “G rand i C l i en t i ” 06/2001 – 10/2007 | Hoogewerf & Cie, una società Fiduciaria importante, Lussemburgo
- Consulenza fiscale internazionale relativa alla tassazione d’impresa (dividendi, royalties, interessi) e persone fisiche.
- Costituzione società Lussemburgo e offshore, gestione degli aspetti
Anastasia Perekrest, M.Sc (Economics) ONELIFE Executive Assistant. She has an advisory experience with several consultancy companies in Luxembourg and Italy where she managed international clients. She is a Certified Tax Advisor and also a member of STEP and ITPA.
© 2017 Onelife
What is Life Science?
4
Healthcare
Healthcare Equipment &
Services
Pharmaceuticals, Biotechnology &
Life Science
Healthcare: The act of taking preventative or necessary medical procedures to improve a person's well-being. Pharmaceutical: The industry discovers, develops, produces, and markets drugs for use as medications. Biotechnology: the manipulation of living organisms or their components to produce commercial products. Life Sciences: include companies in the fields of biotechnology, pharmaceuticals, biomedical technologies, nutraceuticals, cosmeceuticals, environmental, …
© 2017 Onelife 5
Source: US Census, Bloomberg, DESA, WHO, American Alzheimer’s Society
The Facts:
• The world’s population is living longer • 50% of all diseases have no cure • Huge need for new drugs • Life Science market growth +8%(y/y) • High number of companies (>3’000) • Great earning potential • M&A and news-flow drive the market
Age
Why Life Science?
Alzheimer’s Disease (AD)
• Over 47 million worldwide have dementia • A new case of AD every 66 seconds • By 2030 over 76 million affected by AD • 1 in 3 seniors dies with AD • > $ 240 billion the AD costs in US • 2nd most feared disease
© 2017 Onelife
The complexity of the Life Science sector
6
• Over 1.5 b$ are the cost of a new drug • 12 years is the average to develop a
new drug • Ca.10% is the probability of success for
a drug entering the clinic • On average there are only 25 new
approved products per year.
27
24
17 21
36
20 22
18 24
26
21
30
39
27
41
50
22
0
10
20
30
40
50
FDA Approvals
1’000 Substances
10’000 Substances
1 New Drug
10 drugs
Years
1 2 3 4 5 6 7 8 9 10 11 12
Discovery
Preclinical
Phase I
Phase III
Market
Phase II
© 2017 Onelife 7
Onelife services:
Companies
• New projects evaluation • R&D project management • Due diligence • Manufacturing evaluation • Cost-saving analysis • Restructuring • Business plans review • Fund raising support
7
Financial Institutions
• Strategy definition • Company evaluation • Support to fund managers • Scientific portfolios analysis • Due diligence M&A
technical support • R&D portfolio risk
assessment
Family Offices
• Strategic planning • Investments in Life Science • Corporate finance • VC decision-making • Technical support • Non-strategic asset sell out • Succession planning
© 2017 Onelife
Onelife model in Life Science
8 8
Sale
/exi
t St
rate
gy
Full Analysis 20-30 Equities
Quantitative Analysis Scouting
• Deep market monitoring • Top level networking • Opinion leader support • Conferences attending • Management interviews
Review &
Follow-up Qualitative Analysis
Database >200
Companies
• Hands-on experience in every stage of the development and the commercial rollout • Unique combination of industry expertise and financial know-how • Direct presence in USA
© 2017 Onelife 9
An example of asset selection (not an actual portfolio)
0
150
1
80
250
Qua
litat
ive
Quantitative 0 50 100 150
NOVN
GILD
MYGN
ENDP
ABBV
Each company has a qualitative and quantitative score. All companies that pass the initial scrutiny, enter the database. A full valuation, based on a risk analysis system, is carried on to objectively assess the investment. Analysis is performed by segment or category.
© 2017 Onelife 10
Lowering the risk
Years
Size
Research Target
Discovery Lead
First Selection
Preclinical Safety
IND Phase
Clinical Phase I
Clinical Phase II
Clinical Phase III
Registration Phase
Launch Phase
CROs Services
Laboratory Services
Toxicology Services
Health Services
Distribution
Legal & Patent
Chemical
Software
Delivery Systems
Devices
Nursing Homes
Global, diversified and late stage
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Legend/size
R&D (500-1b$)
PH1 (1-10 b$)
PH (>10 b$)
© 2017 Onelife
• Life Science UCITS V fund • Open-end unlimited duration • Medium-long risk profile • Daily NAV in USD • 1’000 USD minimum investment • 1.18% All in fee • Tax transparent in FL, CH, D, A
11
Onelife Fund
www.onelifefund.li ISIN: LI0269512732
BB: ONELIFU LE
© 2017 Onelife
Track record and experience (not back testing)
12
• PSF better in downturn and in positive cycle • Over 80% return in 7 years
• Over 93 mio USD AUM • Volatility 10.87 - Beta 0.28
MSCI World Index Prospera Senectute Fund Sicav-SIF
1 year delay
Source: Bloomberg
© 2017 Onelife
Onelife AG: an entrepreneurial vehicle
• Onelife AG is an entrepreneurial investment holding company.
• Onelife AG is NOT a VC fund.
• Onelife AG invests its financial recourses only in innovative small and medium sized companies (SME).
• Onelife AG has already invested in several companies in different sectors diversifying and limiting the risks.
13
Exit
Investment
Investment
Years
Final objective is to speed up the growth and generate high value for all stakeholders.
© 2017 Onelife
Onelife AG: Investment criteria
• Region: Europe, Switzerland and USA • Phase: From prototype… to expansion (including succession situation) • Criteria: Leaders with large market potential and clear business model • Exclusion Criteria: Non ethical sector as per UN PRI
• Investment: up to € 10 Mio. per target (minimum € 1 Mio.) • Form: Equity or equity related financing instruments • Horizon: ~10 years or more (buy and hold) • Condition: Experienced management team, growing turnover and positive EBITDA
14
© 2017 Onelife
Onelife AG: Last Investments • HeiQ Materials (www.heiqmaterials.com) is a Swiss high-tech
company producing high performance sustainable ‘effects’ for textiles.
15
• Sphinx Tools (www.sphinx-tools.ch) is the leading company in the manufacture and distribution of precision tools for machining by chip removal.
• APR (www.apr.ch) is Swiss integrated healthcare company, developing innovative, value added products and proprietary drug delivery systems.
• Arktis (www.arktis-detectors.com) develops and sells a technology platform for detecting ionizing materials, enabling several applications in numerous vertical markets.
© 2017 Onelife
Corporate responsibility
• Strong commitment to ethical projects. • Strong ESG (Environment, Social,
Governance) principles • Actively involved in United Nation
Principle for Responsible Investment (UNPRI).
• 10% Commitment of profits to public interest organizations.
16
© 2017 Onelife 17
Why Onelife?
• Focus only in the Life Science Sector • Unique combination of Industry Expertise and Financial know-how • Over 70 years of combined experience • Direct presence in USA • Team is privately invested in the company • 10 years of track records • Ethical and social responsible company
© 2017 Onelife 18 18
Via Cantonale 1 6900 Lugano Switzerland Phone: +41 (0)91 924 24 00 E-mail: [email protected]
Onelife SA is a Swiss private corporation. Although utmost care has been exercised in the drafting of this presentation, Onelife SA assume no liability for the information contained herein. The details in this presentation are given for information purposes only and do not constitute an offer or a promotion that invites to purchase shares in any Onelife activity. Also, this presentation does not constitute investment advice and pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. Past performance is not a reliable indicator of future results. This presentation might contain forward-looking statements, including, but not limited to, statements relating to future market developments. While these forward-looking statements represent our carefully researched judgments and expectations, uncertainties and various risk factors could cause actual developments and results to differ materially from our statements.
ONELIFE SA